However, studies have shown Vemurafenib (BRAF inhibitor) alters uptake of Fludeoxyglucose (FDG) in melanoma cells harbouring the BRAFV600E mutation [31, 32], with changes being noted particularly in Glucose transporters 1/3 (GLUT1/3) [33]. Here, SLC2A1 is linked to melanoma.